Status: Recruiting
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
This is a single-site, open-label Phase 1 clinical trial evaluating the feasibility, safety, and preliminary activity of autologous GPC2-targeted chimeric antigen receptor (CAR) T cells administered via intracerebroventricular (ICV) infusion in children and young adults with relapsed or refractory medulloblastoma or other eligible Central Nervous System (CNS) embryonal tumors.
Participants needed: 18
Trial details
Phase: Phase 1Age: 1-30Biological sex: AllType: InterventionalSponsor: Stanford UniversityUpdated: Jan 27, 2026Locations: 1
Eligibility criteria
Diagnosis: Histologically confirmed diagnosis of medulloblastoma or other primar... [+29]
Any patient with metastatic disease OUTSIDE the CNS. [+12]